<DOC>
	<DOCNO>NCT00004175</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel , doxorubicin , cyclophosphamide treat woman previously untreated stage III breast cancer .</brief_summary>
	<brief_title>Docetaxel , Doxorubicin , Cyclophosphamide Treating Women With Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical response rate docetaxel , doxorubicin , cyclophosphamide primary therapy woman stage III breast cancer . II . Determine pathologic complete response rate treatment regimen patient population . III . Assess side effect toxicity profile treatment regimen patient . OUTLINE : This open label , multicenter study . Patients receive doxorubicin IV 5-10 minute follow cyclophosphamide IV 5-10 minute docetaxel IV 1 hour . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Within 5 week follow completion chemotherapy , operable patient achieve complete partial response undergo mastectomy , segmental mastectomy , lumpectomy nodal dissection . Patients positive surgical tumor margin may undergo additional surgical procedure . Patients follow survival . PROJECTED ACCRUAL : A total 40 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm previously untreated , stage III adenocarcinoma breast At least one bidimensionally and/or unidimensionally measurable lesion No evidence disease outside breast chest wall , except ipsilateral axillary lymph node Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 5 time ULN No acute hepatitis Renal : Creatinine great 1.5 mg/dL No uncontrolled hypercalcemia Cardiovascular : No congestive heart failure LVEF normal No angina pectoris No uncontrolled cardiac arrhythmia No significant heart disease No myocardial infarction within past year No superior vena cava syndrome No deep vein thrombosis require anticoagulant therapy Neurologic : No dementia No seizures No concurrent grade 2 great peripheral neuropathy Other : No medical instability No active infection No gastrointestinal bleeding No uncontrolled diabetes No psychological , familial , sociological , geographical condition circumstance would preclude study No malignancy within past 5 year except curatively treat basal cell skin cancer carcinoma situ cervix No history hypersensitivity polysorbate 80 Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy breast cancer Chemotherapy : No prior chemotherapy breast cancer Endocrine therapy : No prior hormonal therapy breast cancer No concurrent corticosteroid except chronic methylprednisolone equivalent 6 month duration 20 mg/day Radiotherapy : Not specify Surgery : Not specify Other : At least 3 week since prior investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>